Nanocarrier Ligands for Selective T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy for cancer faces challenges in selectively targeting cancer cells while avoiding normal cells, as checkpoint blockade strategies can lead to non-specific T cell activation and autoimmunity due to the ubiquitous expression of target receptors on both cell types.
Innovation Solution
The use of nanocarrier-associated ligands to selectively enhance the activation of antigen-experienced cells by binding to microclustered receptors, which are formed upon antigen exposure, thereby promoting targeted immune responses without activating naive cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint blockade antibodies (anti-CTLA-4, anti-PD-1) are administered to block negative regulatory pathways, then anti-tumor immune responses are enhanced, but non-specific T cell activation occurs leading to autoimmunity
Solution Approach 1:
The patent applies local quality by creating microclusters of ligand-binding receptors on the surface of antigen-presenting cells through antigen exposure. These microclusters provide a localized high-density region of receptors that can be selectively targeted by nanocarrier-associated ligands, thereby concentrating the immune activation effect specifically at the site of antigen recognition rather than causing widespread non-specific activation
Solution Approach 2:
The patent employs preliminary action by first exposing antigen-presenting cells to a selected antigen to generate microclustered ligand-binding receptors before administering the nanocarrier-associated ligands. This preliminary antigen exposure creates a preparatory state where only cells that have encountered the specific antigen possess the microclustered receptors, allowing subsequent selective targeting without activating naive cells
2Measurement precision
If antibodies are used to target receptors on infected or tumor cells, then selective targeting is achieved, but non-specific binding to normal cells expressing the same receptor occurs
Solution Approach 1:
The patent creates a local quality distinction between microclustered receptors on antigen-experienced cells and dispersed receptors on naive cells. The microclusters represent localized regions of high receptor density that are physically distinct from the uniform distribution on naive cell surfaces, enabling selective binding of nanocarrier-associated ligands to microclustered regions while avoiding off-target binding to dispersed receptors
Solution Approach 2:
The patent uses preliminary action by pre-exposing antigen-presenting cells to antigen to generate microclustered receptors before administering the therapeutic ligands. This preliminary step ensures that only cells with relevant antigen exposure history develop the microclustered structure, providing a temporal window for selective targeting before treatment begins
Data Source
AI summary
The presently disclosed subject matter provides methods and compositions for activation of clustered receptors on a target cell using nanocarrier-associated ligands, particularly methods and compositions for targeted activation of clustered receptors on antigen-experienced T cells using nanocarrier-associated antibodies.